Patents by Inventor Daniel B. Hall
Daniel B. Hall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240139289Abstract: The invention provides a long-acting parathyroid hormone peptide (PTH) that is retained in a subject's blood serum for periods of time that greatly exceed the natural hormone. The long-acting PTH is conjugated to at the carbon 3 position of a non-hormonal vitamin D via a scaffold of discreet length that facilitates its purification, detection, solubility, and efficacy at the PTH receptor (PTHR). The PTH may be conjugated to the non-hormonal vitamin D via a 36 mer poly(ethylene glycol) moiety (PTH-PEG36-VitD). The invention also provides optimized manufacturing methods and formulations. The PTH-PEG36-VitD has a vastly-improved serum half-life and bioavailability when compared to a non-conjugated PTH peptide. PTH-PEG36-VitD also significantly increases serum calcium, reduces urinary calcium, and reduces serum phosphate.Type: ApplicationFiled: September 14, 2023Publication date: May 2, 2024Applicant: Extend Biosciences, Inc.Inventors: Tarik Soliman, Daniel B. Hall, Rachel Covitz, Garry Musso, Caroline Hill, Ahmet Vakkasoglu, Poul Strange, Tilmann M. Brotz
-
Publication number: 20220409697Abstract: The invention provides non-hormonal Vitamin D conjugated to G-CSF or compounds with G-CSF activity or GM-CSF or compounds having GM-CSF activity singly or in combination that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms.Type: ApplicationFiled: October 19, 2020Publication date: December 29, 2022Applicants: RAMEA LLC, Extend Biosciences Inc.Inventors: Russell J. Barron, Tarik Soliman, Daniel B. Hall
-
Patent number: 11116816Abstract: The invention provides a parathyroid hormone (PTH) compound comprising a PTH peptide. The PTH compound has a significantly increased bioavailability or circulating half-life when compared to a bioavailability or a circulating half-life of a native form of the PTH peptide. The PTH compound has a significantly greater serum concentration at multiple timepoints post-administration to a rat when compared to that of a native PTH peptide.Type: GrantFiled: January 29, 2019Date of Patent: September 14, 2021Assignee: Extend Biosciences, Inc.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
-
Publication number: 20210008153Abstract: The invention provides non-hormonal vitamin D conjugated to apelin proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. In some embodiments, the vitamin D targeting groups are coupled to the apelin proteins via the third carbon on the vitamin D backbone.Type: ApplicationFiled: July 3, 2020Publication date: January 14, 2021Applicant: Extend Biosciences, Inc.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
-
Patent number: 10702574Abstract: The invention provides non-hormonal vitamin D conjugated to apelin proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. In some embodiments, the vitamin D targeting groups are coupled to the apelin proteins via the third carbon on the vitamin D backbone.Type: GrantFiled: February 11, 2017Date of Patent: July 7, 2020Assignee: Extend Biosciences, Inc.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
-
Patent number: 10420819Abstract: The invention provides non-hormonal vitamin D conjugated to insulin peptides that result in the peptides having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are coupled to the insulin peptides via the third carbon on the vitamin D backbone.Type: GrantFiled: March 23, 2017Date of Patent: September 24, 2019Assignee: Extend Biosciences, Inc.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Howard Sard, Vishnumurthy Hegde
-
Patent number: 10406202Abstract: The invention provides non-hormonal vitamin D conjugated via the third carbon on the vitamin D backbone to parathyroid hormone (PTH) proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms.Type: GrantFiled: July 12, 2018Date of Patent: September 10, 2019Assignee: Extend Biosciences, Inc.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
-
Publication number: 20190183966Abstract: The invention provides a parathyroid hormone (PTH) compound comprising a PTH peptide. The PTH compound has a significantly increased bioavailability or circulating half-life when compared to a bioavailability or a circulating half-life of a native form of the PTH peptide. The PTH compound has a significantly greater serum concentration at multiple timepoints post-administration to a rat when compared to that of a native PTH peptide.Type: ApplicationFiled: January 29, 2019Publication date: June 20, 2019Applicant: Extend Biosciences, Inc.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
-
Publication number: 20180311307Abstract: The invention provides non-hormonal vitamin D conjugated via the third carbon on the vitamin D backbone to parathyroid hormone (PTH) proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms.Type: ApplicationFiled: July 12, 2018Publication date: November 1, 2018Applicant: Extend Biosciences, Inc.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
-
Patent number: 9789197Abstract: The invention provides non-hormonal vitamin D conjugated to therapeutic RNA compounds that result in the compounds having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are coupled to the therapeutic RNA compounds via the third carbon on the vitamin D backbone.Type: GrantFiled: October 21, 2015Date of Patent: October 17, 2017Assignee: Extend Biosciences, Inc.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Howard P. Sard, Vishnumurthy Hegde
-
Publication number: 20170252410Abstract: The invention provides non-hormonal vitamin D conjugated to insulin peptides that result in the peptides having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are coupled to the insulin peptides via the third carbon on the vitamin D backbone.Type: ApplicationFiled: March 23, 2017Publication date: September 7, 2017Applicant: Extend Biosciences, Inc.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Howard Sard, Vishnumurthy Hegde
-
Publication number: 20170216449Abstract: The invention provides non-hormonal vitamin D conjugated to apelin proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. In some embodiments, the vitamin D targeting groups are coupled to the apelin proteins via the third carbon on the vitamin D backbone.Type: ApplicationFiled: February 11, 2017Publication date: August 3, 2017Applicant: Extend Biosciences, Inc.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
-
Patent number: 9616109Abstract: The invention provides non-hormonal vitamin D conjugated to insulin peptides that result in the peptides having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are coupled to the insulin peptides via the third carbon on the vitamin D backbone.Type: GrantFiled: October 21, 2015Date of Patent: April 11, 2017Assignee: Extend Biosciences, Inc.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Howard Sard, Vishnumurthy Hegde
-
Patent number: 9585934Abstract: The invention provides non-hormonal vitamin D conjugated to apelin proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. In some embodiments, the vitamin D targeting groups are coupled to the apelin proteins via the third carbon on the vitamin D backbone.Type: GrantFiled: October 21, 2015Date of Patent: March 7, 2017Assignee: Extend Biosciences, Inc.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
-
Publication number: 20160114001Abstract: The invention provides non-hormonal vitamin D conjugated to insulin peptides that result in the peptides having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are coupled to the insulin peptides via the third carbon on the vitamin D backbone.Type: ApplicationFiled: October 21, 2015Publication date: April 28, 2016Applicant: EXTEND BIOSCIENCES, INC.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Howard Sard, Vishnumurthy Hegde
-
Publication number: 20160113993Abstract: The invention provides non-hormonal vitamin D conjugated to apelin proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. In some embodiments, the vitamin D targeting groups are coupled to the apelin proteins via the third carbon on the vitamin D backbone.Type: ApplicationFiled: October 21, 2015Publication date: April 28, 2016Applicant: EXTEND BIOSCIENCES, INC.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
-
Publication number: 20160114049Abstract: The invention provides non-hormonal vitamin D conjugated to therapeutic RNA compounds that result in the compounds having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are coupled to the therapeutic RNA compounds via the third carbon on the vitamin D backbone.Type: ApplicationFiled: October 21, 2015Publication date: April 28, 2016Applicant: EXTEND BIOSCIENCES, INC.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Howard P. Sard, Vishnumurthy Hegde
-
Patent number: 8638435Abstract: The disclosure relates to bioassays, as well as related devices and methods for detecting targets. The targets may be molecules and/or biological products that a user is interested in analyzing to determine information such as their presence and/or concentration in a sample.Type: GrantFiled: July 27, 2011Date of Patent: January 28, 2014Assignee: Radiation Monitoring Devices, Inc.Inventors: Louis H. Strong, Clark M. Edson, Senerath Palamakumbura, Daniel B. Hall, Gyula Varadi
-
Publication number: 20120050736Abstract: The disclosure relates to bioassays, as well as related devices and methods for detecting targets. The targets may be molecules and/or biological products that a user is interested in analyzing to determine information such as their presence and/or concentration in a sample.Type: ApplicationFiled: July 27, 2011Publication date: March 1, 2012Applicant: Radiation Monitoring Devices, Inc.Inventors: Louis H. Strong, Clark M. Edson, Senerath Palamakumbura, Daniel B. Hall, Gyula Varadi